Boston Therapeutics, Inc. (Form: 8-K/A, Received: 10/30/2015 12:07:01)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 24, 2015

BOSTON THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-54586	27-0801073
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

1750 Elm Street, Manchester, NH 03104

(Address of principal executive offices) (zip code)

(Registrant's telephone number, including area code)

49 Front Street, Suite 206

Rockville Centre, New York 11570

Phone: (516) 833-5034

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

Item 3.02 Unregistered Sales of Equity Securities

Item 2.03 Creation of a Direct Financial Obligation or an Off-Balance Sheet Arrangement of a

On October 23, 2015, Boston Therapeutics, Inc. (the "Company") entered into a letter amendment with CJY Holdings Limited ("CJY") whereby the parties amended that certain Securities Purchase Agreement entered between the parties on September 24, 2015 to allow for an increase in the aggregate investment by CJY to $1,050,000 (the "Financing").

In connection with the Financing, on September 24, 2015 and October 20, 2015, the Company issued to CJY two Convertible Promissory Notes (the "CJY Notes") in the amounts of $750,000 and $300,000, respectively. The CJY Notes bear interest of 10% and are payable three years from the date of issuance. Prior to the maturity dates of the CJY Notes, CJY may elect to convert all or part of the CJY Notes, plus accrued interest, into shares of common stock of the Company at a conversion rate of $0.05 per share. The closings of the Financing occurred on September 24, 2015 and October 20, 2015 in the aggregate amount of $1,050,000.

As of the date hereof, the Company is obligated on CJY Notes in the principal amount of $1,050,000 in connection with the Financing. The CJY Notes are debt obligations arising other than in the ordinary course of business, which constitute direct financial obligations of the Company.

The foregoing information is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full text of those agreements, each of which is attached an exhibit to this Current Report on Form 8-K. Readers should review those agreements for a complete understanding of the terms and conditions associated with this transaction.

Item 9.01 Financial Statements and Exhibits

Exhibit No.	Description
4.1	Letter Amendment by and between Boston Therapeutics, Inc. and CJY Holdings Limited
4.2	Form of Securities Purchase Agreement by and between Boston Therapeutics, Inc. and CJY Holdings Limited (1)
4.3	Form of 10% Convertible Promissory Note issued to CJY Holdings Limited (1)

(1) Incorporated by reference to the Form 8-K Current Report filed with the Securities Exchange Commission on October 2, 2015.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BOSTON THERAPEUTICS, INC.

Date: October 30, 2015	By: /s/David Platt
	Name: David Platt
	Title: Chief Executive Officer

Boston Therapeutics Inc.

303 East Wacker Drive, Suite 1040

Chicago, Illinois 60601

October 23, 2015

CJY Holdings Limited

12 Repulse Bay Road

Repulse Bay, Hong Kong

Re:

Securities Purchase Agreement dated September 24, 2015 (the “SPA”) by and between Boston Therapeutics Inc. and CJY Holdings Limited

Gentlemen:

Reference is hereby made to the SPA. By executing this letter, the undersigned investor agrees that the offering amount shall be increased from $750,000 to $1,050,000. Accordingly, it is hereby agreed to by the parties that Section 1(d) of the Agreement shall be amended and restated to state the following:

" d. Subsequent Financing . The Note is intended to provide necessary bridge financing to the Company prior to an anticipated financing in the near future of an amount up to $1,050,000 which is expected to be structured as convertible preferred stock (the "Preferred Financing" ). Upon the closing of the Preferred Financing, the Note shall automatically convert into the Preferred Financing."

We kindly request that you execute this letter below indicating that you agree with the above amendment.

Sincerely,

Boston Therapeutics Inc.

By: /s/David Platt

Name: David Platt

Title: CEO and Director

AGREED AND ACKNOWLEDGED:

CJY Holdings Limited

By: /s/Cheng Chi Him

Name: Cheng Chi Him

Title: